Therapeutic Outcomes and Electrophysiological Biomarkers in Anti-Myelin-Associated Glycoprotein Neuropathy: A Multicenter Cohort Study in South Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Unlike other immune-mediated neuropathies, anti-myelin-associated glycoprotein (MAG) neuropathy is often refractory to immunotherapy. It is necessary to compare the relative efficacies of various immunotherapies and develop objective biomarkers in order to optimize its clinical management. Methods This study recruited 91 patients with high anti-MAG antibody titers from 7 tertiary hospitals in South Korea. We analyzed the baseline characteristics, therapeutic outcomes, and nerve conduction study (NCS) findings of 68 patients and excluded 23 false positive cases. Results The rate of positive responses to treatment was highest using zanubrutinib (50%) and rituximab (36.4%), followed by corticosteroids (16.7%), immunosuppressants (9.5%), intravenous immunoglobulin (5%), and plasma exchange (0%). Disability and weakness were significantly associated with multiple NCS parameters at the time of diagnosis, especially distal compound muscle action potential (CMAP) amplitudes. Moreover, the longitudinal trajectory of the average CMAP amplitudes paralleled the clinical courses, with a 16.2 percentile decrease as an optimal cutoff for predicting a clinical exacerbation (area under the receiver operating characteristic curve=0.792). Conclusions Our study supports the use of NCS as an objective marker for estimating disease burden and tracking clinical changes in patients with anti-MAG neuropathy. We have described the beneficial effects of rituximab and a new drug, zanubrutinib, compared with conventional immunotherapies.
Abstract
Background and Purpose Unlike other immune-mediated neuropathies, anti-myelin-associated glycoprotein (MAG) neuropathy is often refractory to immunotherapy. It is necessary to compare the relative efficacies of various immunotherapies and develop objective biomarkers in order to optimize its clinical management. Methods This study recruited 91 patients with high anti-MAG antibody titers from 7 tertiary hospitals in South Korea. We analyzed the baseline characteristics, therapeutic outcomes, and nerve conduction study (NCS) findings of 68 patients and excluded 23 false positive cases. Results The rate of positive responses to treatment was highest using zanubrutinib (50%) and rituximab (36.4%), followed by corticosteroids (16.7%), immunosuppressants (9.5%), intravenous immunoglobulin (5%), and plasma exchange (0%). Disability and weakness were significantly associated with multiple NCS parameters at the time of diagnosis, especially distal compound muscle action potential (CMAP) amplitudes. Moreover, the longitudinal trajectory of the average CMAP amplitudes paralleled the clinical courses, with a 16.2 percentile decrease as an optimal cutoff for predicting a clinical exacerbation (area under the receiver operating characteristic curve=0.792). Conclusions Our study supports the use of NCS as an objective marker for estimating disease burden and tracking clinical changes in patients with anti-MAG neuropathy. We have described the beneficial effects of rituximab and a new drug, zanubrutinib, compared with conventional immunotherapies.
참고문헌 (54)
- Steck AJ, "Anti-MAG neuropathy : from biology to clinical management", J Neuroimmunol, 361, pp.577725~ (2021)
- Dalakas MC, "Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies", Ther Adv Neurol Disord, 11, pp.1756285617746640~ (2018)
- Delmont E, "Determinants of health-related quality of life in anti-MAG neuropathy : a cross-sectional multicentre European study", J Peripher Nerv Syst, 22, pp.27~33 (2017)
- Nobile-Orazio E, "Longterm prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies", Brain, 123(Pt 4), pp.710~717 (2000)
- Smith IS, "The natural history of chronic demyelinating neuropathy associated with benign IgM paraproteinaemia. A clinical and neurophysiological study", Brain, 117(Pt 5), pp.949~957 (1994)
- Niermeijer JM, "Prognosis of polyneuropathy due to IgM monoclonal gammopathy : a prospective cohort study", Neurology, 74, pp.406~412 (2010)
- Lunn MP, "Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies", Cochrane Database Syst Rev, 10, pp.CD002827~ (2016)
- Comi G, "A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy", J Neurol, 249, pp.1370~1377 (2002)
- Dalakas MC, "Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy", Ann Neurol, 65, pp.286~293 (2009)
- Delmont E, "Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies", J Neurol, 258, pp.1717~1719 (2011)
- Niermeijer JM, "Rituximab for polyneuropathy with IgM monoclonal gammopathy", J Neurol Neurosurg Psychiatry, 80, pp.1036~1039 (2009)
- Niermeijer JM, "Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy", Neurology, 69, pp.50~59 (2007)
- Dalakas MC, "A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy", Ann Neurol, 40, pp.792~795 (1996)
- Renaud S, "High-dose rituximab and anti-MAG-associated polyneuropathy", Neurology, 66, pp.742~744 (2006)
- Léger JM, "Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy", Neurology, 80, pp.2217~2225 (2013)
- Benedetti L, "Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M", J Peripher Nerv Syst, 12, pp.102~107 (2007)
- Campagnolo M, "IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy", J Neurol Neurosurg Psychiatry, 88, pp.1094~1097 (2017)
- Gazzola S, "Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy", J Neurol Sci, 377, pp.144~148 (2017)
- Parisi M, "Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy : clinical, hematological and neurophysiological correlations during 2 years of follow-up", Eur J Neurol, 29, pp.3611~3622 (2022)
- Svahn J, "AntiMAG antibodies in 202 patients : clinicopathological and therapeutic features", J Neurol Neurosurg Psychiatry, 89, pp.499~505 (2018)
- Tang MH, "Prognostic factor of poor outcome in anti-MAG neuropathy : clinical and electrophysiological analysis of a French cohort", J Neurol, 267, pp.561~571 (2020)
- Castellani F, "The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy", Neurol Neuroimmunol Neuroinflamm, 7, pp.e720~ (2020)
- Rakocevic G, "Obinutuzumab, a potent anti-B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy", Neurol Neuroimmunol Neuroinflamm, 5, pp.e460~ (2018)
- Gruson B, "Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy", J Peripher Nerv Syst, 16, pp.180~185 (2011)
- Magy L, "Heterogeneity of polyneuropathy associated with anti-MAG antibodies", J Immunol Res, 2015, pp.450391~ (2015)
- Pruppers MH, "Recent advances in outcome measures in IgM-anti-MAG+ neuropathies", Curr Opin Neurol, 28, pp.486~493 (2015)
- Hänggi P, "Decrease in serum anti-MAG autoantibodies is associated with therapy response in patients with anti-MAG neuropathy : retrospective study", Neurol Neuroimmunol Neuroinflamm, 9, pp.e1109~ (2021)
- Galassi G, "Long-term disability and prognostic factors in polyneuropathy associated with anti-myelin-associated glycoprotein(MAG)antibodies", Int J Neurosci, 127, pp.439~447 (2017)
- Amaador K, "Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy", J Neurol, 269, pp.3700~3705 (2022)
- Capasso M, "Can electrophysiology differentiate polyneuropathy with anti-MAG", SGPG antibodies from chronic inflammatory demyelinating polyneuropathy?, 2002, pp.113, 346~353
- Attarian S, "Terminal latency index and modified F ratio in distinction of chronic demyelinating neuropathies", Clin Neurophysiol, 112, pp.457~463 (2001)
- Lozeron P, "Is distal motor and", or sensory demyelination a distinctive feature of anti-MAG neuropathy?, 2016, pp.263, 1761~1770
- Gesquière-Dando A, "Are electrophysiological features related to disability in patients with anti-MAG neuropathy?", Neurophysiol Clin, 47, pp.75~81 (2017)
- Bourque PR, "Temporal evolution of nerve conduction study abnormalities in anti-myelin-associated glycoprotein neuropathy", Muscle Nerve, 63, pp.401~404 (2021)
- Zara G, "Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy", Clin Neurophysiol, 122, pp.2518~2522 (2011)
- Breiner A, "INCAT disability score : a critical analysis of its measurement properties", Muscle Nerve, 50, pp.164~169 (2014)
- Kleyweg RP, "Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome", Muscle Nerve, 14, pp.1103~1109 (1991)
- Tam CS, "Zanubrutinib(BGB-3111)plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma", Blood Adv, 4, pp.4802~4811 (2020)
- Fialho D, "Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate", J Neurol Neurosurg Psychiatry, 77, pp.544~547 (2006)
- Bus SRM, "Clinical outcome of CIDP one year after start of treatment : a prospective cohort study", J Neurol, 269, pp.945~955 (2022)
- Min YG, "Dissociated leg muscle atrophy in amyotrophic lateral sclerosis", motor neuron disease : the ‘split-leg’ sign, 2020, pp.10, 15661~
- Doneddu PE, "A diagnostic score for anti-myelin-associated-glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti-myelin-associated-glycoprotein antibody", Eur J Neurol, 30, pp.501~510 (2023)
- Luigetti M, "Clinical and pathological heterogeneity in a series of 31 patients with IgM-related neuropathy", J Neurol Sci, 319, pp.75~80 (2012)
- Brooks BR, "El Escorial revisited : revised criteria for the diagnosis of amyotrophic lateral sclerosis", Amyotroph Lateral Scler Other Motor Neuron Disord, 1, pp.293~299 (2000)
- Emilien D, "Diagnostic utility of auto antibodies in inflammatory nerve disorders", J Neuromuscul Dis, 2, pp.107~112 (2015)
- Tim RW, "Repetitive nerve stimulation studies in the Lambert-Eaton myasthenic syndrome", Muscle Nerve, 17, pp.995~1001 (1994)
- Zis P, "Anti-MAG associated cerebellar ataxia and response to rituximab", J Neurol, 265, pp.115~118 (2018)
- Liberatore G, "Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy", J Neuroimmunol, 345, pp.577288~ (2020)
- Van den Bergh PYK, "European Academy of Neurology", Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy : report of a joint task force-second revision, 2021, pp.28, 3556~3583
- Pestronk A, "Treatment of IgM antibody associated polyneuropathies using rituximab", J Neurol Neurosurg Psychiatry, 74, pp.485~489 (2003)
- Mahévas M, "Long-lived plasma cells in autoimmunity : lessons from B-cell depleting therapy", Front Immunol, 4, pp.494~ (2013)
- Benedetti L, "B-cell-activating factor in rituximab-treated patients with anti-MAG polyneuropathy", J Neurol Neurosurg Psychiatry, 82, pp.1291~1294 (2011)
- Lim JH, "Plasma cells arise from differentiation of clonal lymphocytes and secrete IgM in Waldenström macroglobulinemia", iScience, 25, pp.104856~ (2022)
- Treon SP, "Ibrutinib in previously treated Waldenström’s macroglobulinemia", N Engl J Med, 372, pp.1430~1440 (2015)